|

Ruxolitinib Phosphate Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: INCB-18424 Phosphate, Jakafi, Jakavi

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • City of Hope Medical Center2

Indications

  • Cancer2
  • Follicular Helper T-Cell Lymphoma, Not Otherwise Specified1
  • Follicular Helper T-Cell Lymphoma, Follicular-Type1
  • Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type1
  • Follicular Helper T-Cell Lymphoma1

Duarte, California2 trials

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 2
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

City of Hope Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.